logo

LMAT

Lemaitre Vascular·NASDAQ
--
--(--)
--
--(--)
9.01 / 10
Outperform

LMAT's fundamental analysis yields an outstanding rating with a 9.0/10 score. Key strengths include a Net income-Revenue of 0.5246 (group 2), Cash-UP of -0.0335 (group 2), ROA of 7.3315 (group 4), and annualized net profit margin on total assets of 9.7753 (group 4), all contributing positively. The Interest coverage ratio at 15.4844 (group 1) and Net profit attributable to parent company shareholders at 100% further reinforce financial health. Only Asset-MV (group 1) and Revenue-MV (group 1) are neutral-to-negative, but their impact is outweighed by stronger profitability metrics, resulting in an overall excellent evaluation.

Fundamental(9.01)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-1.41
Score2/3
Weight0.91%
1M Return0.09%
ROA (%)
Value7.33
Score3/3
Weight12.37%
1M Return1.03%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight-17.40%
1M Return-1.71%
Net income-Revenue
Value0.52
Score2/3
Weight34.91%
1M Return2.59%
Cash-UP
Value-0.03
Score3/3
Weight50.93%
1M Return3.93%
Annualized net profit margin on total assets (%)
Value9.78
Score3/3
Weight12.37%
1M Return1.03%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-19.61%
1M Return-1.95%
Asset-MV
Value-0.50
Score0/3
Weight-32.86%
1M Return-3.57%
Cash-MV
Value-0.70
Score2/3
Weight43.81%
1M Return3.31%
Net profit / Total profit (%)
Value76.80
Score3/3
Weight14.56%
1M Return1.20%
Is LMAT undervalued or overvalued?
  • LMAT scores 9.01/10 on fundamentals and holds a Discounted valuation at present. Backed by its 11.77% ROE, 22.14% net margin, 37.18 P/E ratio, 5.23 P/B ratio, and 27.57% earnings growth, these metrics solidify its Outperform investment rating.